Malaria - A Drug Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--Sep 18, 2018--Technavio has announced their latest . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of malaria. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005996/en/
Technavio has published a new report on the drug development pipeline for the treatment of malaria, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Malaria: An overview
Malaria is a life-threatening disease caused by the Plasmodium parasite, which is transmitted by infected female mosquitoes of the genus Anopheles. These infected mosquitoes release the Plasmodium parasite into the human’s bloodstream. These parasites move toward the liver where they mature and replicate. Later they spread through the bloodstream and infect healthy red blood cells (RBCs) in the body. They multiply inside the RBCs, causing fever, sweating, and nausea which occur in a cycle and last 2-3 days. Malaria can also be transmitted during organ transplantation, blood transfusion, and through shared needles and syringes.
Malaria mainly occurs in tropical countries, with the highest concentration in Africa. According to the World Bank, sub-Saharan Africa accounts for 90% of the global malaria cases. Countries in APAC such as India are also highly exposed to the disease. The World Bank has been supporting malaria control programs and financing the healthcare organizations in procuring preventive measures such as mosquito nets, antimalaria drugs, and diagnostic test kits.
Malaria: Segmentation of pipeline molecules
Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with more than 43% of the pipeline molecules administered through this mode.
Between companies and institutions, institutions led the drug development space for the treatment of malaria. Some of the key players include Agilvax, Eisai, Sanofi, Novartis, and GENVEC.
Some of the key topics covered in the report include:
1. Scope of the Report
2. Regulatory Framework
3. Drug Development LandscapeDrugs under development
4. Drug Development StrategiesTherapies employed Route of administration Therapeutic modality Mechanism of action
5. Recruitment StrategiesGeographical coverage Recruitment status Gender Age
6. Key CompaniesType of players Company overview
7. Discontinued and Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005996/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/18/2018 02:23 PM/DISC: 09/18/2018 02:23 PM